These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7083208)

  • 41. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
    Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
    Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in serum estrogen levels in women during tamoxifen therapy.
    Lum SS; Woltering EA; Fletcher WS; Pommier RF
    Am J Surg; 1997 May; 173(5):399-402. PubMed ID: 9168075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Sequential changes in hormone levels in postmenopausal breast cancer patients under long-term treatment with an aromatase inhibitor. Kanagawa AI Study Group].
    Fukuda M; Watanabe H; Suda T; Shimizu S
    Gan To Kagaku Ryoho; 1999 Dec; 26(14):2201-8. PubMed ID: 10635305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days.
    Kloosterboer HJ; Löfgren L; von Schoulz E; von Schoultz B; Verheul HA
    Reprod Sci; 2007 Feb; 14(2):151-9. PubMed ID: 17636226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Androstenedione metabolism in patients with endometrial cancer.
    Calanog A; Sall S; Gordon GG; Southren AL
    Am J Obstet Gynecol; 1977 Nov; 129(5):553-6. PubMed ID: 910844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiprogestins, a new form of endocrine therapy for human breast cancer.
    Klijn JG; de Jong FH; Bakker GH; Lamberts SW; Rodenburg CJ; Alexieva-Figusch J
    Cancer Res; 1989 Jun; 49(11):2851-6. PubMed ID: 2720645
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
    Smuc T; Rizner TL
    Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings.
    Tominaga T; Suzuki T
    Anticancer Res; 2003; 23(4):3533-42. PubMed ID: 12926103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Additive effects of aminoglutethimide, testololactone, and 4-hydroxyandrostenedione as inhibitors of aromatase.
    Santner SJ; Rosen H; Osawa Y; Santen RJ
    J Steroid Biochem; 1984 Jun; 20(6A):1239-42. PubMed ID: 6748639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence that brain aromatization regulates LH secretion in the male dog.
    Worgul TJ; Santen RJ; Samojlik E; Irwin G; Falvo RE
    Am J Physiol; 1981 Sep; 241(3):E246-50. PubMed ID: 7282924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple forms of aromatase and response of breast cancer aromatase to antiplacental aromatase II antibodies.
    Osawa Y; Tochigi B; Higashiyama T; Yarborough C; Nakamura T; Yamamoto T
    Cancer Res; 1982 Aug; 42(8 Suppl):3299s-3306s. PubMed ID: 6177401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medical adrenalectomy and plasma steroids in advanced breast carcinoma.
    Newsome HH; Brown PW; Terz JJ; Lawrence W
    Surgery; 1978 Jan; 83(1):83-9. PubMed ID: 619476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peripheral production of oestrogens in postmenopausal women [proceedings].
    Hutton JD; Murray MA; Goodall A; Baxendale P; Jacobs HS; James VH
    J Endocrinol; 1978 May; 77(2):1P-2P. PubMed ID: 660030
    [No Abstract]   [Full Text] [Related]  

  • 55. Androgen and estrogen dynamics: stability over a two year interval in peri-menopausal women.
    Longcope C; Johnston CC
    J Steroid Biochem; 1990 Jan; 35(1):91-5. PubMed ID: 2308332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estrogen and androgen levels in women treated with radiation for cervical cancer--possible influence on breast cancer risk.
    Eby NL; Boice JD; Gold EB; Hoover RN; Loriaux DL
    Am J Epidemiol; 1989 Mar; 129(3):527-32. PubMed ID: 2783832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. delta 1-testololactone: clinical trials'.
    Segaloff A
    Cancer Res; 1982 Aug; 42(8 Suppl):3387s-3388s. PubMed ID: 7044522
    [No Abstract]   [Full Text] [Related]  

  • 58. The intracellular control of aromatase activity by 5 alpha-reduced androgens in human breast carcinoma cells in culture.
    Perel E; Stolee KH; Kharlip L; Blackstein ME; Killinger DW
    J Clin Endocrinol Metab; 1984 Mar; 58(3):467-72. PubMed ID: 6693545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The inhibitory effect of miconazole on aromatase activity for androstenedione in human placental and ovarian preparations].
    Yamamoto T; Urabe M; Okada H
    Nihon Naibunpi Gakkai Zasshi; 1987 Nov; 63(11):1379-85. PubMed ID: 3443212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estrone and estradiol in patients with cirrhosis of the liver: effects of ACTH and dexamethasone.
    Kley HK; Krüskemper HL; Keck E
    J Clin Endocrinol Metab; 1976 Sep; 43(3):557-60. PubMed ID: 182710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.